UNSPSC 51263701: Adaprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C26H39NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XP9911I1WL, chemically known as (+/-)-2-(1-adamantyl)ethyl (p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetate, but generally known as adaprolol, which bears US NIH Compound Identifier 60732. European Medicines Agency schedules adaprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05262MIG.

Most nations schedule adaprolol under HS 29221980 and SITC 51461. As of Q4 2014, ADAPROLOL remains the US FDA Preferred Term for this commodity. Adaprolol bears US NLM identifiers UMLS ID C0645354 and NCI Concept Code C77938. SMILES: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)OCCC23CC4CC(C2)CC(C4)C3)O.

UNSPSC 51263701 Adaprolol, a Commodity code, shows minimal recent state and local procurement activity aligned with the code's pharmaceutical scope. The recent opportunities tagged under this code involve naloxone acquisition and direct-to-manufacturer prescription program planning — products and services substantially different from adaprolol, a beta-blocker medication. State and local governments do not appear to be actively soliciting adaprolol under this code at present.

The mismatch between the code's nominal scope and the recent opportunities suggests either administrative mis-tagging or that adaprolol procurement through state and local channels remains dormant. Seminole County, Florida's naloxone and drug deactivation systems bid (IFB60459723LAS, due Jul 26, 2023) and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescriptions (HHS0017013, due Apr 3, 2026) represent the only recent records available. Neither directly reflects adaprolol demand. Without active solicitations under this code, business development professionals should monitor the code for future activity rather than pursue current opportunities.